RESUMO
A study in 100 women with postmenopausal bleedings has identified internal endometriosis of the uterine corpus in 50 of them. The diagnosis was made on the basis of past history, hysteroscopy, ultrasound scanning, roentgenotelevision hysterosalpingography, histological examination of resected uterine and adnexal tissues. Thirty patients were operated on and found to have internal endometriosis of different locations and extent as well as nodular adenomyosis. Endometriosis was functionally progressive in 29 patients and regressive in 1 patient, as was confirmed with luminescence histological examination. Ovarian hyperplasia and/or luteinization of the theca interna, stromal hyperplasia, focal thecomatosis and granulosa cell tumour which were present in 56.7% of the patients accounted for active endometriosis. Duration of postmenopause did not influence the functional activity of internal endometriosis.
Assuntos
Endometriose/diagnóstico , Endométrio/patologia , Menopausa , Neoplasias Uterinas/diagnóstico , Idoso , Atrofia/patologia , Hiperplasia Endometrial/patologia , Endometriose/patologia , Feminino , Humanos , Pessoa de Meia-Idade , Neoplasias Uterinas/patologiaAssuntos
Endometriose/diagnóstico por imagem , Histerossalpingografia/métodos , Televisão/métodos , Neoplasias Uterinas/diagnóstico por imagem , Adulto , Diagnóstico Diferencial , Endometriose/patologia , Endometriose/cirurgia , Feminino , Humanos , Óleo Iodado , Leiomioma/diagnóstico por imagem , Leiomioma/patologia , Leiomioma/cirurgia , Pessoa de Meia-Idade , Neoplasias Uterinas/patologia , Neoplasias Uterinas/cirurgia , Útero/patologiaRESUMO
Clinical and metabolic effects of depot-injections of estradiol valerianate-dehydroepiandrosterone enanthate at a 1:50 ratio (Gynodian-depot) in the treatment of severe clinical manifestations of the vegetoneurotic syndrome were evaluated in menopuasal patients after hysterectomy for uterine myoma. Favourable comprehensive effects of the drug were noted, which in most patients contributed to the elimination or significant alleviation of major vegetoneurotic, psychoemotional and metabolic-endocrine disorders. An effective combination of the estrogenic and androgenic hormonal components and their ratios, coupled with very insignificant side-effects, is an important advantage of the drug, permitting its large-scale use for the control of menopausal complications, particularly after surgery for a uterine tumour.
